SEATTLE, June 10, 2021 — Icosavax, Inc. today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo

First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus

Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening

Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration

· Two-component virus-like particle (VLP) technology developed at the Institute for Protein Design exclusively licensed from the University of Washington